GI physician: NAFLD is major health problem | FODMAPs can have both harmful and helpful GI effects | Study looks at cardiovascular risks in celiac disease
February 13, 2015
CONNECT WITH ACG®  FacebookTwitter
Digestive Health SmartBrief
From American College of Gastroenterology

Top Story
GI physician: NAFLD is major health problem
Nonalcoholic fatty liver disease is a major public health risk linked to other problems such as obesity and alcohol consumption, writes Dr. Hyder Jamal, a gastroenterologist for St. Joseph Health practicing in Fullerton, Calif. He writes that NAFLD puts a great deal of stress on the liver and likely will become the leading cause of liver transplants in the U.S. Blog (2/9)
Share: LinkedInTwitterFacebookGoogle+Email
Guide to Healthy Living
FODMAPs can have both harmful and helpful GI effects
Some people who think they may be gluten sensitive may actually be sensitive to FODMAPs, carbohydrates that are not broken down and absorbed in the small intestine, according to a study by Australian gastroenterology professor Peter Gibson. Adopting a low-FODMAP diet can help with GI symptoms, but the downside is that foods high in FODMAPs ferment in the large intestine, stimulating the growth of healthy gut bacteria. The Washington Post (tiered subscription model) (2/9)
Share: LinkedInTwitterFacebookGoogle+Email
Study looks at cardiovascular risks in celiac disease
Persistent villous atrophy does not affect the risk of heart disease or atrial fibrillation among patients with celiac disease, according to a study from researchers at Karolinska University Hospital in Stockholm. The researchers said celiac disease patients have an overall higher mortality risk from cardiovascular causes but villous atrophy linked to gluten exposure did not affect that risk. Medscape (free registration) (2/10)
Share: LinkedInTwitterFacebookGoogle+Email
New dietary guidelines may drop warning on cholesterol
The U.S. Dietary Guidelines Advisory Committee is expected to drop its caution against consuming cholesterol when it releases updated recommendations this year. The decision would coincide with a change in thinking among many nutrition experts about cholesterol in foods and the impact on heart disease risk. The Washington Post (tiered subscription model)/Wonkblog (2/10), USA Today (2/12)
Share: LinkedInTwitterFacebookGoogle+Email
Diagnosis & Treatment
Hepatitis C cocktail removes virus in 6 weeks, drugmaker says
ACH-3102, an experimental hepatitis C drug from Achillion Pharmaceuticals, when combined with sofosbuvir from Gilead Sciences, can remove the virus from a patient in six weeks, says Achillion. The company will begin testing ACH-3102 in combination with its nucleotide analog inhibitor ACH-3422 in hopes of finding a doublet that could provide competition for two other well-known hepatitis C treatments. Reuters (2/9)
Share: LinkedInTwitterFacebookGoogle+Email
Study examines effects of portal vein thrombosis on liver disease
Cirrhosis patients who developed portal vein thrombosis may not also see their liver disease worsen, researchers said. The study included more than 1,200 patients in France and Belgium. Healio (free registration) (2/10)
Share: LinkedInTwitterFacebookGoogle+Email
Research reconstructs early stages of colorectal tumors
Researchers from the University of Southern California said they studied colorectal cancer tumors to find out how they originate, and then reconstructed early cell divisions that occur when tumors are too small to detect. Dr. Darryl Shibata said it was like going back in time to look at the beginnings of tumors, which may have important implications for prevention and treatment of colorectal tumors. Science World Report (2/9)
Share: LinkedInTwitterFacebookGoogle+Email
Policy Watch
FDA urges drugmakers to create "consumer-friendly" DTC print ads
The FDA has released new draft guidance urging drugmakers to provide "consumer-friendly" summaries in promotional materials and other direct-to-consumer print advertisements. Drugmakers no longer need to include the full package insert, but they still must include information about serious risks, including interactions with other drugs, according to the guidance. The FDA said most consumers don't understand the technical information included in the insert. The Wall Street Journal (tiered subscription model)/Pharmalot Blog (2/6), (2/6)
Share: LinkedInTwitterFacebookGoogle+Email
Ideas for simplifying the ACA emerge from policy conference
Panelists at the National Health Policy Conference said the Affordable Care Act is too complicated and suggested ways to simplify it, such as repealing the individual mandate and instead allowing insurers to charge more for people who have not maintained continuous coverage. Kaiser Health News (2/9)
Share: LinkedInTwitterFacebookGoogle+Email
Patient's Perspective
Of ostomies and pregnancy
"It makes me very happy to say that it is still possible to get pregnant with an ostomy! ... [My surgeon] told me that having the surgery should not affect my ability to carry a child, however, it could make it more difficult to conceive in the first place. I believe it has something to do with scar tissue from the surgery and also, just anytime you go moving things around in your stomach/gut-area it can affect the way your body functions." -- blog post from Stephanie on
Share: LinkedInTwitterFacebookGoogle+Email
The Last Word
News and information from the American College of Gastroenterology
Gallstone disease: Are you at risk?
Gallstones are one of the most common gastrointestinal problems, especially for women. Women between the ages of 20 and 60 years are three times more likely to develop gallstones than men. Learn more about the symptoms and risk factors for developing gallstone disease.
Share: LinkedInTwitterFacebookGoogle+Email
Happiness grows at our own firesides, and is not to be picked in strangers' gardens."
-- Douglas Jerrold,
British writer
Share: LinkedInTwitterFacebookGoogle+Email
Contact Your Doctor
American College of Gastroenterology
Contact ACG
American College of Gastroenterology
P.O. Box 342260
Bethesda, MD 20827-2260
The presence of any advertisement in this newsletter does not constitute endorsement of the associated service, product, or company by the American College of Gastroenterology, SmartBrief, or any participating physicians.
The information contained in Digestive Health SmartBrief is not intended to be medical advice. Consult your physician before making any decisions regarding your health care.
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tara Rosenzweig
Advertising:  Rebecca Adelson
  P: 202.618.5665

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information